Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

One down for Parkinsonís
March 2020
SHARING OPTIONS:

PARIS & DIJON, France—Mid-February saw Servier and Oncodesign reach the first significant milestone in their strategic partnership to research and develop drug candidates for Parkinson’s disease, triggering a €1-million milestone payment for Oncodesign. The companies are focusing on LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix platform.
 
Dr. Philippe Genne, CEO and founder of Oncodesign, said: “Following the selection a few weeks ago of our first candidate drug inhibitor of RIPK2, this is very good news coming from our strategic collaboration with Servier. The collaboration works perfectly and both teams are up to the challenges. The results were obtained sooner than expected, which allowed us to reach our first milestone several months in advance, showing more than ever the important mastery of the Nanocyclix chemistry by our teams. We are very honored to collaborate successfully with Servier.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.